Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LDT715
- Development stage
- Preclinical
- Lead developer
- Universidade Estadual de Campinas
- Modality
- Small Molecules
01
Overview
LDT715 is a small molecule inhibitor targeting *Plasmodium falciparum* Aurora kinase-2 (PfArk-2), a serine/threonine kinase essential for the parasite's development across multiple stages of its life cycle [6818]. Discovered through virtual screening of the ChemBridge commercial library, LDT715 has demonstrated potent in vitro antimalarial activity against both chloroquine-sensitive (3D7) and chloroquine-resistant (Dd2) strains of *P. falciparum*, with an EC50 of less than 100 nM [6818]. It exhibits low cytotoxicity in mammalian cells (COS-7 and HepG2) and acts rapidly during the early stages of asexual parasite development [6818].
Beyond the preview
Go deeper on LDT715.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LDT715.